Servier is a privately owned pharmaceutical company, governed by a non-profit foundation that is committed to therapeutic progress to serve patient needs. Servier has a long-standing commitment to research and development.
Worldwide approximately 25% of branded product turnover is reinvested into research and development through the Servier Foundation, with half of that investment dedicated to research to help fight cancer.
Servier has significant investment in new products in early development in the areas of Oncology and Haematology with broad research and development platforms in cancer cell apoptosis and immuno-oncology. Servier Australia is also home to the Asia-Pacific clinical trial hub currently managing 8 cancer clinical trials in Australia.
Servier is proud to support innovative partnering programs with world class institutions including WEHI in Australia to further advance scientific understanding in the area of oncology. For further information see the website
Servier Australia’s oncology products include Lonsurf® (trifluridine/tipiracil), Onivyde® (nanoliposomal irinotecan as sucrosofate), Muphoran (fotemustine) and Oncaspar (pegaspargase).